Announcement PDF Emyria ASX Announcement | 9 October 2026 1 ASX RELEASE. 9 October 2026 RETIREMENT OF NON-EXECUTIVE DIRECTOR, PROFESSOR SIR JOHN TOOKE Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in delivering evidence- based intensive mental-health care, advises that Non-Executive Director Professor Sir John Tooke will retire from the Board at the conclusion of the AGM on 12 November 2026 to dedicate more time to personal endeavours. Professor Tooke joined the Board on 10 February 2020 and over the past 6.5 years has helped guide Emyria through a period of significant transformation, including the expansion of its clinical services footprint and emergence as a leading developer of innovative, evidence-based mental health treatments. A consultant physician with more than 30 years' experience across diabetes, endocrinology, vascular medicine and internal medicine, and an extensive academic and research background, Professor Tooke has added deep clinical insight to the Board’s strategic agenda. Emyria Executive Chair, Greg Hutchinson commented: “On behalf of the Emyria Board, and the Company more broadly, I would like to sincerely thank Professor Tooke for his significant contribution since he joined as a Non-Executive Director in 2020. His expertise has helped shaped our strategic direction and clinical development. We wish him every happiness and success for the future.” As part of its ongoing succession planning, the Company is reviewing the composition of the Board to ensure an appropriate balance of skills, experience, independence and sector expertise as Emyria continues to execute its strategic priorities. This release has been approved by the Board of Emyria. For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson Executive Chair 1300 153 355 | investors@emyria.com ASX RELEASE. Emyria ASX Announcement | 9 October 2026 2 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. generates informs